Understanding Adenomyosis: Causes, Symptoms and Treatment Options

Speciality: Obstetrics and Gynecology


Speaker:

Dr. Asha R.Rao | MD, DGO, FICOG, Infertility Specialist, Obstetrician, Gynecologist

Prof. S Shantha Kumari | MD, DNB, FICOG, FRCPI (Ireland) FRCOG (UK), President FOGSI 2021-2023, Honorary Treasurer FIGO 2021-2023

Dr. Madhuri Patel | MD, DGO, FICOG, Hon. Clinical Associate

Dr. Nandita P Palshetkar | MBBS, MD - Obstetrics & Gynaecology, FCPS - Mid. & Gynae, Fellow of Indian College of Obstetrics and Gynecology (FICOG), Infertility Specialist, Laparoscopic Surgeon (Obs & Gyn)

Description:

A warm welcome to all the medical professionals in this interesting session of management of enigmatic adenomyosis. In this webinar, the speakers, Dr. Asha R.Rao, Prof. S Shantha Kumari, Dr. Madhuri Patel, Dr. Nandita P Palshetkar and panel have shared the important facts associated with the management of enigmatic adenomyosis. 

Adenomyosis is a gynecologic condition that causes the endometrial tissue in the lining of the uterus to grow into the muscular wall of the uterus causing enlargement of the uterus. Basically these are not harmful but can lead to very heavy menstrual bleeding along with severe pain, thereby, affecting regular lifestyle.

Adenomyosis is traditionally considered as an enigmatic disease. It is a uterine disease that affects many women of reproductive age and is a contributing factor for pelvic pain, heavy menstrual bleeding (HMB), and subfertility. 

Therefore,  you are going to have an overall knowledge on adenomyosis management using advanced treatment approaches such as IVF. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
 


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study opens up possibility of bespoke prostate cancer treatment

2.

Why Encouragement May Not Improve Motivation in Depression

3.

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients

4.

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

5.

Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot